Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Allergy and Immunology

Standard of Care Treatment and Daily Management

At a Glance

Daily management of autosomal dominant partial IL6ST deficiency is individualized: prevent infections with specialist-guided medicines, protect the skin and lungs, replace antibodies when needed, and report symptoms early. Stem cell transplant remains an exceptional investigational option.

Managing autosomal dominant (AD) partial IL6ST deficiency requires a proactive, “multi-front” approach. Because this condition is so rare, there is no single, universally mandated treatment protocol. Instead, your care team will likely use a framework based on established guidelines for STAT3-Hyper-IgE syndrome (STAT3-HIES), which shares many of the same immune and clinical challenges [1][2].

The Foundation: Infection Prevention

The primary goal of daily management is to prevent infections before they can damage your lungs or skin.

  • Antibiotic Prophylaxis: Many patients take an individualized prophylactic-dose antibiotic—most commonly trimethoprim-sulfamethoxazole—to prevent Staphylococcus aureus infections [3][4]. This is extrapolated from other HIES-like disorders where it reduced the number of skin abscesses and pneumonias [5]. The decision requires individualized specialist review of your age, kidney function, and allergies.
  • Antifungal Prophylaxis: This is not universal for all patients. It is typically reserved for those who have developed structural lung changes, such as pneumatoceles (air-filled cysts) or bronchiectasis (scarred airways), which can “trap” fungal spores like Aspergillus. The decision is highly individualized based on cultures and imaging, and distinguishes prevention from treatment [6][7].
  • Immunoglobulin Replacement (IVIG/SCIG): If your body does not produce enough protective antibodies after vaccination, or if you continue to get infections despite antibiotics, your doctor may recommend immunoglobulin replacement therapy [8]. This can help reduce infections in selected patients [7][9].

Skin and Allergy Care

Meticulous skin care is essential to prevent the “cold abscesses” and infections common in this syndrome.

  • Eczema Management: Standard care involves frequent moisturizing and topical treatments. However, for severe cases that don’t respond to creams, a biologic called dupilumab has been utilized off-label with reported success in clearing rashes [10][11]. Evidence is limited to small series and requires coordinated dermatology and immunology monitoring.
  • Caution with Steroids: Topical steroids are commonly used, but systemic steroids (like oral prednisone) must be used with extreme caution in IL6ST deficiency. Systemic steroids can further “muffle” your immune system, potentially masking a serious infection or making you more vulnerable to invasive fungal disease [12][13]. Do not start or stop either without your clinician.

Pulmonary Health: Monitoring and Protection

Because lung damage can occur even without high fevers or typical signs of illness, ongoing pulmonary care is critical [4].

  • Routine Imaging: Your team may use individualized CT scans to monitor for “silent” damage like bronchiectasis or new cysts [14][15], minimizing radiation where possible.
  • Airway Clearance: If you have lung scarring, your doctor may recommend chest physiotherapy or exercise to help clear mucus and prevent bacteria from settling in the airways [7].

Specialized Considerations: HSCT

Hematopoietic Stem Cell Transplant (HSCT)—sometimes called a bone marrow transplant—is an investigational treatment that replaces the immune system. In other forms of HIES, like DOCK8 deficiency, it is often curative [16].

  • For AD-IL6ST: The role of HSCT is an investigational, exceptional expert-center consideration. In STAT3-HIES, research shows it may reduce infections, but it may not correct GP130 defects in non-blood tissues or reverse damage that has already happened [17][18].
  • Personalized Decisions: Because the risks of transplant are significant, this option is usually only discussed if a patient has life-threatening infections or progressive lung damage that isn’t responding to standard preventive care [19][20].

A Proactive Partnership

Because your immune system’s “alarm bell” (the acute-phase response) is quiet, you and your caregivers are the most important members of your medical team. Promptly reporting new symptoms—even if they seem minor—allows for the “aggressive” treatment of infections that is central to maintaining long-term health [4].

Common questions in this guide

What treatments may help prevent infections in partial IL6ST deficiency?
There is no single treatment plan for this rare disorder. An immunology team may recommend an individualized preventive antibiotic, often trimethoprim-sulfamethoxazole, and may add antifungal prevention or immunoglobulin replacement when lung changes, cultures, antibody responses, or infection history make them appropriate.
When is IVIG or SCIG used for partial IL6ST deficiency?
Immunoglobulin replacement may be considered when vaccination does not produce enough protective antibodies or when infections continue despite preventive antibiotics. IVIG is given into a vein, while SCIG is given under the skin, and the decision is individualized with an immunology specialist.
Does everyone with partial IL6ST deficiency need antifungal medicine?
No. Preventive antifungal treatment is usually considered only for selected patients, such as those with pneumatoceles or bronchiectasis, or when cultures and imaging suggest increased fungal risk. Preventing infection is different from treating an infection that is already present.
How can I manage eczema without increasing infection risk?
Frequent moisturizing and prescribed topical treatments are the usual foundation of eczema care. Dupilumab has been used off-label for severe eczema that does not respond to creams, but evidence is limited and it requires dermatology and immunology follow-up. Systemic steroids such as oral prednisone should not be started or stopped without clinician guidance because they can mask infection and increase vulnerability to invasive fungal disease.
How should lung health be monitored in partial IL6ST deficiency?
Your care team may use individualized CT scans to look for bronchiectasis, new cysts, or other lung damage while limiting radiation when possible. If scarring is present, chest physiotherapy, airway-clearance techniques, or exercise may help remove mucus. New or worsening cough or shortness of breath should be reported promptly, even without a high fever.
Could a bone marrow transplant treat AD partial IL6ST deficiency?
Hematopoietic stem cell transplant is investigational for AD partial IL6ST deficiency and is generally considered only at an expert center in exceptional situations. It may be discussed for life-threatening infections or progressive lung damage that does not respond to preventive care, but transplant carries significant risks and may not repair defects in tissues outside the blood or reverse existing damage.
Why do infections need prompt treatment if I do not have a fever?
Partial IL6ST deficiency can blunt the body's acute-phase alarm response, so a serious infection may not cause a high fever or other typical warning signs. Reporting even mild new symptoms promptly helps clinicians investigate and treat infections early.

Get notified when new evidence is published on Autosomal dominant combined immunodeficiency due to partial IL6ST deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (20)
  1. 1

    Dominant-negative mutations in human IL6ST underlie hyper-IgE syndrome.

    Béziat V, Tavernier SJ, Chen YH, et al.

    The Journal of experimental medicine 2020; (217(6)) doi:10.1084/jem.20191804.

    PMID: 32207811
  2. 2

    How I Treat: STAT3 hyper IgE syndrome.

    Murray CE, Jannoud E, Prader S, Grimbacher B

    Journal of human immunity 2026; (2(4)):e20260038 doi:10.70962/jhi.20260038.

    PMID: 42221228
  3. 3

    Autosomal Dominant Hyper-IgE Syndrome in the USIDNET Registry.

    Gernez Y, Freeman AF, Holland SM, et al.

    The journal of allergy and clinical immunology. In practice 2018; (6(3)):996-1001 doi:10.1016/j.jaip.2017.06.041.

    PMID: 28939137
  4. 4

    Hemoptysis in a Patient with Elevated Immunoglobulin E.

    Gernez Y, Tsuang A, Smith TD, et al.

    The journal of allergy and clinical immunology. In practice 2016; (4(6)):1054-1058 doi:10.1016/j.jaip.2016.08.003.

    PMID: 27693026
  5. 5

    Intraoral and maxillofacial abnormalities in patients with autosomal dominant hyper-IgE syndrome.

    Tar I, Szegedi M, Krasuska-Sławińska E, et al.

    Central-European journal of immunology 2023; (48(3)):228-236 doi:10.5114/ceji.2023.130874.

    PMID: 37901871
  6. 6

    Inborn errors of immunity and invasive fungal infections: presentation and management.

    Paccoud O, Warris A, Puel A, Lanternier F

    Current opinion in infectious diseases 2024; (37(6)):464-473 doi:10.1097/QCO.0000000000001062.

    PMID: 39259685
  7. 7

    Lung disease in STAT3 hyper-IgE syndrome requires intense therapy.

    Kröner C, Neumann J, Ley-Zaporozhan J, et al.

    Allergy 2019; (74(9)):1691-1702 doi:10.1111/all.13753.

    PMID: 30793327
  8. 8

    Humoral immunodeficiencies: conferred risk of infections and benefits of immunoglobulin replacement therapy.

    Gernez Y, Baker MG, Maglione PJ

    Transfusion 2018; (58 Suppl 3()):3056-3064 doi:10.1111/trf.15020.

    PMID: 30536429
  9. 9

    Reduced Immunoglobulin (Ig) G Response to Staphylococcus aureus in STAT3 Hyper-IgE Syndrome.

    Stentzel S, Hagl B, Abel F, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2017; (64(9)):1279-1282 doi:10.1093/cid/cix140.

    PMID: 28203787
  10. 10

    Improvement in Atopic Dermatitis and Recurrent Infection With Dupilumab in Children With Distinct Genetic Types of Hyper-IgE Syndrome: A Case Series and Literature Review.

    Dick JK, Boull C, Pozos TC, Maguiness SM

    Pediatric dermatology 2025; (42(2)):376-382 doi:10.1111/pde.15780.

    PMID: 39420803
  11. 11

    Dominant-negative signal transducer and activator of transcription (STAT)3 variants in adult patients: A single center experience.

    Shamriz O, Rubin L, Simon AJ, et al.

    Frontiers in immunology 2022; (13()):1044933 doi:10.3389/fimmu.2022.1044933.

    PMID: 36605204
  12. 12

    [STAT3 gene-related hyper-IgE syndrome complicated by pulmonary aspergillosis: a case report].

    Xu WS, Wan YH, Zhao JQ, Mu XD

    Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases 2026; (49(6)):673-677 doi:10.3760/cma.j.cn112147-20250729-00450.

    PMID: 42236459
  13. 13

    Invasive Pulmonary Aspergillosis in a Young Adult With Hyperimmunoglobulin E Syndrome and Hypogammaglobulinemia Following Rituximab Therapy.

    Pandrangi GK, Golechha RN, Mills LR, et al.

    Cureus 2026; (18(1)):e102562 doi:10.7759/cureus.102562.

    PMID: 41769421
  14. 14

    Primary immunodeficiency diseases of adults: a review of pulmonary complication imaging findings.

    Grenier PA, Brun AL, Longchampt E, et al.

    European radiology 2024; (34(6)):4142-4154 doi:10.1007/s00330-023-10334-7.

    PMID: 37935849
  15. 15

    Clinical features, genetics, treatment, and long-term outcomes of STAT3 hyper-IgE syndrome: Single-center cohort analysis.

    Freeman AF, Wang C, Urban A, et al.

    The Journal of allergy and clinical immunology 2026; (158(2)):569-581 doi:10.1016/j.jaci.2026.04.012.

    PMID: 42061468
  16. 16

    Hyper-IgE syndromes in pediatrics: clinical spectrum, differential diagnosis, and management.

    Mikulić S, Mihaljević MV, Kraljević D

    Folia medica 2026; (68(4)) doi:10.3897/folmed.68.e173262.

    PMID: 42677762
  17. 17

    Hematopoietic Stem Cell Transplantation Resolves the Immune Deficit Associated with STAT3-Dominant-Negative Hyper-IgE Syndrome.

    Harrison SC, Tsilifis C, Slatter MA, et al.

    Journal of clinical immunology 2021; (41(5)):934-943 doi:10.1007/s10875-021-00971-2.

    PMID: 33523338
  18. 18

    The Potential and Limits of Hematopoietic Stem Cell Transplantation for the Treatment of Autosomal Dominant Hyper-IgE Syndrome.

    Yanagimachi M, Ohya T, Yokosuka T, et al.

    Journal of clinical immunology 2016; (36(5)):511-6 doi:10.1007/s10875-016-0278-1.

    PMID: 27091139
  19. 19

    STAT3 Hyper-IgE Syndrome-an Update and Unanswered Questions.

    Tsilifis C, Freeman AF, Gennery AR

    Journal of clinical immunology 2021; (41(5)):864-880 doi:10.1007/s10875-021-01051-1.

    PMID: 33932191
  20. 20

    Hematopoietic Stem Cell Transplantation and Vasculopathy Associated With STAT3-Dominant-Negative Hyper-IgE Syndrome.

    Ponsford MJ, Clark J, Mock J, et al.

    Frontiers in pediatrics 2020; (8()):575 doi:10.3389/fped.2020.00575.

    PMID: 33014947

This page is for informational purposes only and does not constitute medical advice. Treatment decisions for partial IL6ST deficiency should be individualized with your immunologist and other specialists.

Guide contents Autosomal dominant combined immunodeficiency due to partial IL6ST deficiency
Research & Literature
04 Understanding Your Lab Results and Diagnosis 06 Long-Term Monitoring, Surveillance, and Building Your Care Team